MCID: BRN028
MIFTS: 74

Brain Cancer

Categories: Cancer diseases, Mental diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Brain Cancer

MalaCards integrated aliases for Brain Cancer:

Name: Brain Cancer 12 54 15
Malignant Neoplasm of Brain 29 71 32
Adult Brain Tumor 12 54 71
Brain Neoplasms 74 44 71
Primary Malignant Neoplasm of Brain 12 71
Neoplasm of Brain 12 6
Brain Neoplasm 12 17
Brain Tumors 54 42
Malignant Primary Brain Neoplasm 12
Adult Malignant Brain Neoplasm 12
Malignant Tumor of Adult Brain 12
Malignant Primary Brain Tumors 54
Malignant Primary Brain Tumor 12
Malignant Tumor of Brain 12
Malignant Brain Tumour 12
Primary Brain Neoplasm 12
Brain Neoplasm, Adult 12
Primary Brain Tumors 15
Brain Tumor, Primary 71
Primary Brain Tumor 12
Brain Tumor Primary 54
Tumor of the Brain 12
Brain Tumor, Adult 20
Bt - Brain Tumour 12
Cancer, Brain 39

Classifications:



External Ids:

Disease Ontology 12 DOID:1319
ICD9CM 34 191 239.6
MeSH 44 D001932
ICD10 32 C71 C71.9
UMLS 71 C0006118 C0153633 C0220624 more

Summaries for Brain Cancer

MedlinePlus : 42 A brain tumor is a growth of abnormal cells in the tissues of the brain. Brain tumors can be benign, with no cancer cells, or malignant, with cancer cells that grow quickly. Some are primary brain tumors, which start in the brain. Others are metastatic, and they start somewhere else in the body and move to the brain. Brain tumors can cause many symptoms. Some of the most common are Headaches, often in the morning Nausea and vomiting Changes in your ability to talk, hear, or see Problems with balance or walking Problems with thinking or memory Feeling weak or sleepy Changes in your mood or behavior Seizures Doctors diagnose brain tumors by doing a neurologic exam and tests including an MRI, CT scan, and biopsy. Treatment options include watchful waiting, surgery, radiation therapy, chemotherapy, and targeted therapy. Targeted therapy uses drugs or other substances that attack cancer cells with less harm to normal cells. Many people get a combination of treatments. NIH: National Cancer Institute

MalaCards based summary : Brain Cancer, also known as malignant neoplasm of brain, is related to li-fraumeni syndrome and tuberous sclerosis, and has symptoms including seizures, tremor and back pain. An important gene associated with Brain Cancer is MIR142 (MicroRNA 142), and among its related pathways/superpathways are ERK Signaling and Activation of cAMP-Dependent PKA. The drugs Sevoflurane and Fentanyl have been mentioned in the context of this disorder. Affiliated tissues include brain, breast and eye, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 A central nervous system cancer that is characterized by the growth of abnormal cells in the tissues of the brain.

Wikipedia : 74 A brain tumor occurs when abnormal cells form within the brain. There are two main types of tumors:... more...

Related Diseases for Brain Cancer

Diseases related to Brain Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 939)
# Related Disease Score Top Affiliating Genes
1 li-fraumeni syndrome 32.8 TP53 PTEN PIK3CA IDH2 IDH1 EGFR
2 tuberous sclerosis 32.3 TP53 PTEN PIK3CA NES
3 brain glioma 32.1 TP53 NES MGMT IDH2 IDH1 EGFR
4 gliomatosis cerebri 32.1 TP53 PTEN NES IDH1 EGFR BRAF
5 supratentorial cancer 32.1 TP53 NES MGMT IDH1 EGFR
6 medulloblastoma 32.0 TP53 PTEN PIK3CA NRAS NES MGMT
7 tuberous sclerosis 1 32.0 TP53 PTEN PIK3CA
8 atypical teratoid rhabdoid tumor 32.0 TP53 MIR142 H3-3A CTNNB1 ALK
9 infratentorial cancer 31.9 TP53 PTEN NES MIR25 MIR142 MGMT
10 glioblastoma 31.5 TP53 PTEN PIK3R1 PIK3CA NRAS NES
11 glioma 31.5 TP53 PTEN PIK3CA MIR25 IDH2 IDH1
12 lung cancer 31.4 TP53 PTPN11 PTEN PIK3R1 PIK3CA NRAS
13 adenoma 31.4 TP53 PIK3CA MGMT CTNNB1 BRAF
14 glioma susceptibility 1 31.3 TP53 IDH2 IDH1 H3-3A DANCR
15 high grade glioma 31.3 TP53 PTEN PIK3CA MGMT EGFR
16 malignant astrocytoma 31.2 TP53 PTEN NES MIR142 MGMT IDH2
17 high grade ependymoma 31.1 TP53 MGMT IDH1 H3-3A EGFR
18 adenocarcinoma 31.0 TP53 PTEN PIK3CA EGFR CTNNB1 BRAF
19 oligodendroglioma 31.0 TP53 PTEN MGMT IDH2 IDH1 EGFR
20 brain stem glioma 31.0 TP53 PIK3CA IDH2 IDH1 H3-3A EGFR
21 childhood medulloblastoma 31.0 TP53 EGFR CTNNB1
22 neurofibroma 30.9 TP53 PTEN EGFR
23 meningioma, familial 30.9 TP53 PTPN11 PTEN PIK3R1 PIK3CA EGFR
24 low grade glioma 30.9 MGMT IDH2 IDH1
25 gemistocytic astrocytoma 30.9 TP53 PTEN IDH2 IDH1
26 small cell carcinoma 30.9 TP53 PTEN EGFR ALK
27 basal cell nevus syndrome 30.9 TP53 PTEN EGFR CTNNB1
28 teratoma 30.9 TP53 PTEN NES CTNNB1
29 cerebral ventricle cancer 30.8 TP53 NES MGMT IDH1 EGFR
30 central nervous system benign neoplasm 30.8 TP53 PTEN IDH1 H3-3A CTNNB1
31 astroblastoma 30.8 NES IDH1 BRAF
32 frontal lobe neoplasm 30.8 TP53 MGMT IDH1 EGFR
33 anaplastic astrocytoma 30.8 TP53 PTEN NES MGMT IDH2 IDH1
34 intrahepatic cholangiocarcinoma 30.8 TP53 IDH2 IDH1 EGFR CTNNB1
35 neuroblastoma 30.7 TP53 PTPN11 PTEN PIK3CA NRAS NES
36 nervous system cancer 30.7 TP53 MIR25 MIR142 MGMT IDH1 EGFR
37 pilomyxoid astrocytoma 30.7 IDH1 H3-3A BRAF
38 pleomorphic xanthoastrocytoma 30.7 TP53 MGMT IDH2 IDH1 H3-3A BRAF
39 renal cell carcinoma, nonpapillary 30.7 TP53 PTEN PIK3CA NRAS MIR142 EGFR
40 temporal lobe neoplasm 30.7 MGMT IDH1
41 carcinosarcoma 30.6 TP53 PTEN PIK3CA EGFR CTNNB1
42 central nervous system cancer 30.6 TP53 PTEN NES MIR142 MGMT IDH2
43 cholangiocarcinoma 30.6 TP53 PIK3CA IDH2 IDH1 EGFR CTNNB1
44 anaplastic oligodendroglioma 30.6 MGMT IDH2
45 transitional cell carcinoma 30.6 TP53 PTEN EPHB2 EGFR BRAF
46 myelodysplastic syndrome 30.6 TP53 PTPN11 PTEN NRAS MGMT IDH2
47 suppression of tumorigenicity 12 30.5 TP53 PTEN PIK3CA IDH1 EGFR CTNNB1
48 peripheral nervous system disease 30.5 TP53 PTEN NES MIR142 EGFR CTNNB1
49 diffuse midline glioma, h3 k27m-mutant 30.5 TP53 NES MGMT IDH1 H3-3A
50 pancreatic adenocarcinoma 30.5 TP53 PIK3CA EGFR CTNNB1 BRAF

Comorbidity relations with Brain Cancer via Phenotypic Disease Network (PDN):


Acute Cystitis Brain Edema
Epilepsy, Focal, with Speech Disorder and with or Without Mental Retardation Hypertension, Essential
Obstructive Hydrocephalus Schizophreniform Disorder

Graphical network of the top 20 diseases related to Brain Cancer:



Diseases related to Brain Cancer

Symptoms & Phenotypes for Brain Cancer

UMLS symptoms related to Brain Cancer:


seizures, tremor, back pain, headache, syncope, pain, chronic pain, sciatica, vertigo/dizziness, sleeplessness

GenomeRNAi Phenotypes related to Brain Cancer according to GeneCards Suite gene sharing:

26 (show all 37)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.19 EGFR PIK3CA
2 Decreased viability GR00055-A-2 10.19 EGFR PIK3CA
3 Decreased viability GR00221-A-1 10.19 ALK EGFR NRAS PIK3CA PIK3R1
4 Decreased viability GR00221-A-2 10.19 PIK3CA
5 Decreased viability GR00221-A-3 10.19 NRAS PIK3R1
6 Decreased viability GR00221-A-4 10.19 ALK EGFR PIK3CA
7 Decreased viability GR00249-S 10.19 ALK
8 Decreased viability GR00402-S-2 10.19 PIK3CA
9 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.15 PIK3R1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-112 10.15 IDH1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-127 10.15 IDH1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-136 10.15 IDH1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-138 10.15 IDH1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.15 BRAF
15 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.15 IDH2
16 Increased shRNA abundance (Z-score > 2) GR00366-A-172 10.15 IDH1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.15 IDH2
18 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.15 IDH2 PIK3R1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-178 10.15 PTPN11
20 Increased shRNA abundance (Z-score > 2) GR00366-A-18 10.15 IDH1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-199 10.15 IDH2 PIK3R1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.15 PIK3R1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-216 10.15 IDH2
24 Increased shRNA abundance (Z-score > 2) GR00366-A-27 10.15 IDH2
25 Increased shRNA abundance (Z-score > 2) GR00366-A-34 10.15 PIK3R1
26 Increased shRNA abundance (Z-score > 2) GR00366-A-39 10.15 IDH1
27 Increased shRNA abundance (Z-score > 2) GR00366-A-42 10.15 IDH2
28 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.15 PIK3R1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.15 BRAF CTNNB1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-60 10.15 PIK3CA
31 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.15 PTPN11
32 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.15 IDH2
33 Increased shRNA abundance (Z-score > 2) GR00366-A-78 10.15 PTPN11
34 Decreased cell migration GR00055-A-1 9.72 ALK EPHB2
35 Decreased cell migration GR00055-A-3 9.72 BRAF EGFR PIK3CA
36 Reduced mammosphere formation GR00396-S 9.17 BRAF EGFR IDH2 NRAS PIK3R1 PTEN
37 Increased focal adhesion (FA) area, decreased number of small and round FAs, increased peripheral FA formation, increased cell spreading GR00210-A 8.85 CTNNB1

MGI Mouse Phenotypes related to Brain Cancer:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.3 ALK BRAF CTNNB1 EGFR EPHB2 MGMT
2 integument MP:0010771 10.21 ALK BRAF CTNNB1 EGFR NRAS PIK3CA
3 neoplasm MP:0002006 10.21 ALK BRAF CTNNB1 EGFR IDH2 MGMT
4 digestive/alimentary MP:0005381 10.14 BRAF CTNNB1 EGFR EPHB2 NRAS PTEN
5 limbs/digits/tail MP:0005371 10.1 BRAF CTNNB1 EGFR IDH2 NRAS PTEN
6 liver/biliary system MP:0005370 10.08 BRAF CTNNB1 EGFR NRAS PIK3R1 PTEN
7 muscle MP:0005369 10.06 BRAF CTNNB1 EGFR PIK3CA PIK3R1 PTEN
8 normal MP:0002873 10.02 ALK BRAF CTNNB1 EGFR NRAS PIK3R1
9 reproductive system MP:0005389 9.96 ACRBP ALK BRAF CTNNB1 EGFR EPHB2
10 no phenotypic analysis MP:0003012 9.95 CTNNB1 EGFR MGMT NRAS PIK3CA PTPN11
11 pigmentation MP:0001186 9.92 ALK BRAF CTNNB1 EGFR NRAS PTEN
12 respiratory system MP:0005388 9.81 ALK BRAF CTNNB1 EGFR IDH1 MGMT
13 skeleton MP:0005390 9.7 ALK BRAF CTNNB1 EGFR IDH1 IDH2
14 vision/eye MP:0005391 9.36 ALK BRAF CTNNB1 EGFR EPHB2 NRAS

Drugs & Therapeutics for Brain Cancer

Drugs for Brain Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 506)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
2
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
3
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
4
Morphine Approved, Investigational Phase 4 57-27-2 5288826
5
Magnesium Sulfate Approved, Investigational, Vet_approved Phase 4 7487-88-9 24083
6
Phenylephrine Approved Phase 4 59-42-7 6041
7
Oxymetazoline Approved, Investigational Phase 4 1491-59-4 4636
8
Ephedrine Approved Phase 4 299-42-3 9294
9
Pseudoephedrine Approved Phase 4 90-82-4 7028
10
Levobupivacaine Approved, Investigational Phase 4 27262-47-1 92253
11
Rocuronium Approved Phase 4 119302-91-9, 143558-00-3 441290
12
Thrombin Approved, Investigational Phase 4
13
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
14
Clevidipine Approved, Investigational Phase 4 167221-71-8
15
Labetalol Approved Phase 4 36894-69-6 3869
16
Hydralazine Approved Phase 4 86-54-4 3637
17
Levetiracetam Approved Phase 4 102767-28-2 441341
18
Pregabalin Approved, Investigational Phase 4 148553-50-8 5486971
19
Amitriptyline Approved Phase 4 50-48-6 2160
20 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
21
Pramipexole Approved, Investigational Phase 4 104632-26-0 59868 119570
22
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
23
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
24
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
25
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
26
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
27
Rotigotine Approved Phase 4 99755-59-6, 92206-54-7 57537
28
Clopidogrel Approved Phase 4 120202-66-6, 113665-84-2 60606
29
Topiramate Approved Phase 4 97240-79-4 5284627
30
Sumatriptan Approved, Investigational Phase 4 103628-46-2 5358
31
Zolmitriptan Approved, Investigational Phase 4 139264-17-8 441240 60857
32
Propranolol Approved, Investigational Phase 4 525-66-6 4946
33
Rivastigmine Approved, Investigational Phase 4 123441-03-2 77991
34
Lamotrigine Approved, Investigational Phase 4 84057-84-1 3878
35
Rizatriptan Approved Phase 4 144034-80-0, 145202-66-0 5078
36
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 68602 5311068
37
Racepinephrine Approved Phase 4 329-65-7 838
38
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
39
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
40
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
41
Glutamic acid Approved, Nutraceutical Phase 4 56-86-0 33032
42
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
43 Cytochrome P-450 CYP3A Inhibitors Phase 4
44 Cytochrome P-450 Enzyme Inhibitors Phase 4
45 Anesthetics Phase 4
46 Narcotics Phase 4
47 Analgesics, Opioid Phase 4
48 alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid Phase 4
49 Calcium, Dietary Phase 4
50 Dexketoprofen trometamol Phase 4

Interventional clinical trials:

(show top 50) (show all 1209)
# Name Status NCT ID Phase Drugs
1 A Single Arm, Multi-center Study to Assess the Efficacy and Safety of Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in Non-squamous Non-small-cell Lung Cancer (NSCLC) Unknown status NCT03799601 Phase 4 Anlotinib;Docetaxel;Carboplatin
2 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Unknown status NCT02478346 Phase 4 Fluorescein Sodium
3 A Randomized, Open Label, Two-way Crossover, Single Dose Bioequivalence Study Comparing Dralitem® Capsules to the Reference Drug Temodal® Capsules in Patients With Primary Tumors of the Central Nervous System Under Fasting Conditions Completed NCT02343081 Phase 4 Temozolomide;Temozolomide
4 Phase II Feasibility Study to Evaluate the Efficacy and Safety of Perampanel in Seizure Patients With Primary Glial Brain Tumors Completed NCT02363933 Phase 4 Perampanel
5 Intra-individual Cross-over Efficacy Evaluation of Dotarem®-Enhanced MRI Compared to Gadovist®/ Gadavist®-Enhanced MRI in the Diagnosis of Brain Tumors Completed NCT02034708 Phase 4 Dotarem®;Gadovist®/Gadavist®
6 Prospective Trial of Intravenous Levetiracetam in Patients With Primary Brain Tumors and at Least One Symptomatic Seizure Who Undergo Biopsy or Cytoreductive Surgery (HELLO-study) Completed NCT00571155 Phase 4 levetiracetam
7 A Prospective, Randomized Trial Comparing Surgery Versus Radiosurgery for the Treatment of Metastatic Brain Tumors Completed NCT00075166 Phase 4
8 A Prospective, Single-Blinded, Randomized Study of Awake vs Intubated General Anesthesia in Patients Undergoing Elective Craniotomy for Supratentorial Glioma Resection Completed NCT02193568 Phase 4
9 Effect of Single Dose of Tramadol on Extubation Response and Quality of Emergence(Cough and Nausea Vomiting) Following Supratentorial Intracranial Surgery Completed NCT02964416 Phase 4 Injection Tramadol
10 The Effect of Dexmedetomidine as an Adjuvant to General Anesthesia on Intelligence Development in Pediatric Patients Undergoing Craniotomy: a Randomized, Double-blind and Placebo-controlled Pilot Trial Completed NCT02810899 Phase 4 dexmedetomidine;normal saline
11 Effective and Safe Morphine Dose for Patient Controlled Anesthesia in Supratentorial Craniotomies Completed NCT04313374 Phase 4 Morphine PCA 1 mg;Morphine PCA 0,5 mg;Placebo
12 A Phase IV Double-blind Multicenter Randomized Crossover Study to Compare 0.10 mmol/kg of Multihance With 0.10 mmol.kg of Magnevist in Magnetic Resonance Imaging(MRI) of the Brain at 3T Completed NCT00395863 Phase 4 Multihance;Arm 2 - Magnevist
13 Influence of Vasopressors on Brain Oxygenation and Microcirculation in Anesthetized Patients With Cerebral Tumors Completed NCT02713087 Phase 4 Ephedrine;Phenylephrine
14 The Effect of Intravenous Single Dose of Magnesium Sulphate on Attenuation of Hemodynamic Pressor Response After Myfield's Clamp Application During Craniotomies Completed NCT03318471 Phase 4 MgSo4;0.9% NaCl
15 The Use of Fentanyl in General Anesthesia for Craniotomy With or Without 0.5% Levobupivacaine Scalp Block: A Randomized Controlled Trial Completed NCT02558569 Phase 4 Levobupivacaine
16 Sugammadex Given for the Reversal of Deep Rocuronium Induced Neuromuscular Blockade Under Sevoflurane Anesthesia in Infants: A Retrospective Study Completed NCT02708056 Phase 4 Sugammadex
17 A Prospective, Randomized, Controlled Phase IV Study to Compare Bioseal Versus Standard of Care as an Adjunct to Hemostasis in Elective Brain Tumor Surgery Completed NCT02034799 Phase 4
18 Impact of Prophylactic Use of Dexmedetomidine on Postoperative Delirium in Patients After Intracranial Operation for Brain Tumor: a Pilot Randomized Controlled Trial Completed NCT04494828 Phase 4 Dexmedetomidine;Normal saline group
19 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
20 Clinical Study to Evaluate the Efficacy of Prophylactic Itraconazole in High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Pediatric Solid Tumors Completed NCT00336531 Phase 4 itraconazole
21 Validation and Verification of 3 Dimensional Laparoscopic System in Laparoscopic Distal Pancreatectomy & Splenectomy Completed NCT02757690 Phase 4
22 The Effect of Pre-incisional Anterior Scalp Block on Intraoperative Opioid Consumption in Adult Patients Undergoing Elective Craniotomy to Remove Tumor: A Prospective Randomized Controlled Completed NCT02057367 Phase 4 Scalp block with 0.5% plain Marcaine;Scalp block with 0.9% normal saline
23 A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients Completed NCT00952081 Phase 4 Clevidipine
24 Effect of Dexmedetomidine on Brain Homeostasis and Neurocognitive Outcome of Patients Undergoing Brain Tumor Exclusion Recruiting NCT04266665 Phase 4 Dexmedetomidine
25 Gemini - Cancer Genetic Testing in Ethnic Populations Recruiting NCT04475640 Phase 4
26 A Shortened Antiepileptic Drug (AED) Course in Surgical Brain Tumor Patients: A Randomized Trial Active, not recruiting NCT02334722 Phase 4 Levetiracetam extended release
27 Quality Improvement and Practice Based Research in Neurology Using the Electronic Medical Record Enrolling by invitation NCT02670161 Phase 4 Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)
28 Dexmedetomidine for Prevention of Postoperative Delirium in Patients After Intracranial Operation for Brain Tumor: a Multicenter Randomized Controlled Trial Not yet recruiting NCT04399343 Phase 4 Dexmedetomidine;Normal saline
29 Effects of Pre-emptive Scalp Infiltration With Ketorolac and Ropivacaine for Postoperative Pain Relief After Elective Supratentorial Craniotomy (PAINLESS) Not yet recruiting NCT04141319 Phase 4 Ketorolac;Ropivacaine;Epinephrine
30 Phase IV GliaSite® Radiation Therapy System Registry Protocol for the Treatment of Resectable Malignant Brain Tumors Terminated NCT00415467 Phase 4
31 Yellow 560 Microscope for Intraoperative Visualization of Fluorescein Stained Intracranial Lesions Terminated NCT02028325 Phase 4 Fluorescein Sodium
32 Phase II GENIUS Trial of GENetically-Informed Therapies for Patients With previoUSly Treated Refractory Metastatic Cancer Withdrawn NCT02000739 Phase 4
33 A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM) Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
34 Role of 3-D Navigable Ultrasound in Resection of Intra-axial Brain Tumors - A Randomized Controlled Study Unknown status NCT02150564 Phase 3
35 PHASE 3 STUDY OF EFFICACY OF TRANEXAMIC ACID IN BRAIN TUMORS RESECTIONS Unknown status NCT01655927 Phase 3 Tranexamic Acid;Placebo: Saline
36 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
37 Proteome-based Personalized Immunotherapy of Malignant Brain Tumors Unknown status NCT01759810 Phase 2, Phase 3
38 Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
39 Comparison of Esmolol and Dexmedetomidine on Sympathetic Control During Intracranial Procedures Unknown status NCT02563288 Phase 3 Esmolol;Dexmedetomidine
40 Phase 3 Study of Stereotactic Radiotherapy of the Postoperative Resection Cavity Versus Whole-Brain Irradiation After Surgical Resection of Single Brain Metastasis Unknown status NCT01535209 Phase 3
41 A Randomized, Phase III Study of Fotemustine Versus the Combination of Fotemustine and Ipilimumab or the Combination of Ipilimumab and Nivolumab in Patients With Metastatic Melanoma With Brain Metastasis Unknown status NCT02460068 Phase 3 Fotemustine;Fotemustine and Ipilimumab;Ipilimumab and nivolumab
42 Gefitinib Alone or With Concomitant Whole Brain Radiotherapy for Patients Harboring an EGFR Mutation With Multiple Brain Metastases From Non-Small-cell Lung Cancer: a Phase II/III Randomized Controlled Trial Unknown status NCT02338011 Phase 2, Phase 3 Gefitinib
43 PRECISE - Phase III Randomized Evaluation of Convection Enhanced Delivery of IL13-PE38QQR Compared to GLIADEL® Wafer With Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
44 Temozolomid (One Week on/One Week Off) Versus Strahlentherapie in Der Primärtherapie Anaplastischer Astrozytome Und Glioblastome Bei älteren Patienten: Eine Randomisierte Phase III-Studie (Methvsalem) Completed NCT01502241 Phase 3 Temozolomide
45 Music Video and Adolescent/Young Adult Resilience During Transplant Completed NCT00305851 Phase 3
46 Phase III Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3 Imatinib mesylate;Hydroxyurea
47 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
48 Intra-individual Comparison Study of Intravenously Administered Magnevist (SH L 451A) on Lesion Detection Ability in MRI After an Initial Dose of 0.1 mmol/kg and After an Additional Dose of 0.1 mmol/kg in Patients With Metastatic Brain Tumor Completed NCT00681551 Phase 3 Magnevist (SH L 451A);Magnevist (SH L 451A)
49 Randomized Phase III Trial of Postoperative Whole Brain Radiation Therapy Compared With Salvage Stereotactic Radiosurgery in Patients With One to Four Brain Metastasis: Japan Clinical Oncology Group Study (JCOG 0504) Completed NCT00280475 Phase 3
50 Randomized Phase III Trial of Xcytrin® (Motexafin Gadolinium) Injection for the Treatment of Brain Metastases in Patients With Non-Small Cell Lung Cancer Undergoing Whole Brain Radiation Therapy Completed NCT00054795 Phase 3 Motexafin Gadolinium

Search NIH Clinical Center for Brain Cancer

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Carmustine
Etoposide
etoposide phosphate
hydroxyurea
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
Lomustine
Mifepristone
peginterferon alfa-2a
peginterferon alfa-2b
Procarbazine
Procarbazine Hydrochloride
Recombinant interferon beta-1a
Recombinant interferon beta-1b

Cochrane evidence based reviews: brain neoplasms

Genetic Tests for Brain Cancer

Genetic tests related to Brain Cancer:

# Genetic test Affiliating Genes
1 Malignant Neoplasm of Brain 29

Anatomical Context for Brain Cancer

MalaCards organs/tissues related to Brain Cancer:

40
Brain, Breast, Eye, T Cells, Endothelial, Cortex, Bone

Publications for Brain Cancer

Articles related to Brain Cancer:

(show top 50) (show all 4041)
# Title Authors PMID Year
1
Evaluating Mismatch Repair/Microsatellite Instability Status Using Cytology Effusion Specimens to Determine Eligibility for Immunotherapy. 42
33367660 2021
2
A-kinase interacting protein 1 is sufficiently expressed and positively associates with WHO grade, meanwhile predicts unfavorable overall survival independently in glioma patients. 42
33530151 2021
3
Ephedrine versus Phenylephrine Effect on Cerebral Blood Flow and Oxygen Consumption in Anesthetized Brain Tumor Patients. 42
33377957 2020
4
Survey of MicroRNA expression in pediatric brain tumors. 47
21157891 2011
5
FasL gene knock-down therapy enhances the antiglioma immune response. 61 54
20406899 2010
6
Mig-6 controls EGFR trafficking and suppresses gliomagenesis. 61 54
20351267 2010
7
MRI-coupled fluorescence tomography quantifies EGFR activity in brain tumors. 61 54
20152724 2010
8
CMDS: a population-based method for identifying recurrent DNA copy number aberrations in cancer from high-resolution data. 61 54
20031968 2010
9
A review of studies on targeting interleukin 4 receptor for central nervous system malignancy. 61 54
19689300 2009
10
VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. 61 54
19333229 2009
11
Therapeutic targeting of g-protein coupled receptor-mediated epidermal growth factor receptor transactivation in human glioma brain tumors. 54 61
18991757 2008
12
Somatic alterations in brain tumors. 61 54
18575738 2008
13
Gene expression profiling of metastatic brain cancer. 61 54
17611651 2007
14
Epidermal growth factor receptor serum levels and prognostic value in malignant gliomas. 54 61
17679463 2007
15
Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors. 54 61
17483310 2007
16
Huntingtin interacting protein 1 is a novel brain tumor marker that associates with epidermal growth factor receptor. 54 61
17440072 2007
17
Interleukin-13 receptor-targeted nanovesicles are a potential therapy for glioblastoma multiforme. 54 61
17172420 2006
18
New roles for galectins in brain tumors--from prognostic markers to therapeutic targets. 61 54
15912884 2005
19
RNA interference and nonviral targeted gene therapy of experimental brain cancer. 54 61
15717065 2005
20
Intravenous RNA interference gene therapy targeting the human epidermal growth factor receptor prolongs survival in intracranial brain cancer. 54 61
15173073 2004
21
Genetic polymorphisms in GSTM1, -P1, -T1, and CYP2E1 and the risk of adult brain tumors. 61 54
12540498 2003
22
Co-delivery of an antisense oligonucleotide and 5-fluorouracil using sustained release poly (lactide-co-glycolide) microsphere formulations for potential combination therapy in cancer. 54 61
11839444 2002
23
Ethnicity delineates different genetic pathways in malignant glioma. 61 54
11358811 2001
24
Treatment of glioblastoma U-87 by systemic administration of an antisense protein kinase C-alpha phosphorothioate oligodeoxynucleotide. 54 61
8700129 1996
25
Development of L-carnosine functionalized iron oxide nanoparticles loaded with dexamethasone for simultaneous therapeutic potential of blood brain barrier crossing and ischemic stroke treatment. 61
33586561 2021
26
Methadone-mediated sensitization of glioblastoma cells is drug and cell line dependent. 61
33315125 2021
27
Aberrant Rac pathway signalling in glioblastoma. 61
31032735 2021
28
Prospective Longitudinal Assessment of Quality of Life and Activities of Daily Living as Patient-Reported Outcome Measures in Recurrent/Progressive Glioma Treated with High-dose Salvage Re-irradiation. 61
32917486 2021
29
Rapid three-dimensional steady-state chemical exchange saturation transfer magnetic resonance imaging. 61
32851659 2021
30
Pre-clinical investigation of mesenchymal stromal cell-derived extracellular vesicles: a systematic review. 61
33541780 2021
31
Clinical practice guidelines for the management of adult diffuse gliomas. 61
33166616 2021
32
Dataset on in-silico investigation on triazole derivatives via molecular modelling approach: A potential glioblastoma inhibitors. 61
33457478 2021
33
An Arf/Rab cascade controls the growth and invasiveness of glioblastoma. 61
33443570 2021
34
Human TERT promoter mutations as a prognostic biomarker in glioma. 61
33547950 2021
35
Development of a prognostic model of glioma based on immune-related genes. 61
33376548 2021
36
Molecular and radiological characterization of glioblastoma multiforme using magnetic resonance imaging. 61
31298508 2021
37
Evaluation of hepatic drug-metabolism for glioblastoma using liver-brain chip. 61
33145669 2021
38
Effects of selective outcome reporting on risk perception. 61
33548295 2021
39
Examining Fear of Cancer Recurrence in Primary Brain Tumor Patients and Their Caregivers Using the Actor-Partner Interdependence Model. 61
33599334 2021
40
Concanavalin A induces apoptosis in a dose-dependent manner by modulating thiol/disulfide homeostasis in C6 glioblastoma cells. 61
33604990 2021
41
Handheld macroscopic Raman spectroscopy imaging instrument for machine-learning-based molecular tissue margins characterization. 61
33580641 2021
42
"A Complete Molecular Atlas of Glioblastoma". 61
33602719 2021
43
Feasibility of a mini-pig model of radiation-induced brain injury to one cerebral hemisphere. 61
33549130 2021
44
Impact of depatuxizumab mafodotin on health-related quality of life and neurological functioning in the phase II EORTC 1410/INTELLANCE 2 trial for EGFR-amplified recurrent glioblastoma. 61
33601293 2021
45
The role of E3 ubiquitin ligases in the development and progression of glioblastoma. 61
33432111 2021
46
Dosimetric evaluation of synthetic CT image generated using a neural network for MR-only brain radiotherapy. 61
33527712 2021
47
Brahma-Related Gene-1 (BRG1) promotes the malignant phenotype of glioblastoma cells. 61
33528916 2021
48
Intraoperative Mass Spectrometry Platform for IDH Mutation Status Prediction, Glioma Diagnosis, and Estimation of Tumor Cell Infiltration. 61
33523209 2021
49
Poly (lactic-co-glycolic acid) & tocopheryl polyethylene glycol succinate nanoparticles for the treatment of different brain cancer. 61
33563201 2021
50
Physiologically Based Pharmacokinetic Modeling of Central Nervous System Pharmacokinetics of CDK4/6 Inhibitors to Guide Selection of Drug and Dosing Regimen for Brain Cancer Treatment. 61
32799335 2021

Variations for Brain Cancer

ClinVar genetic disease variations for Brain Cancer:

6 (show top 50) (show all 238)
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 EGFR NM_005228.5(EGFR):c.865_866delinsAT (p.Ala289Ile) Indel Likely pathogenic 376398 rs1057519887 7:55221821-55221822 7:55154128-55154129
2 TP53 NM_000546.5(TP53):c.404G>T (p.Cys135Phe) SNV Likely pathogenic 376559 rs587781991 17:7578526-7578526 17:7675208-7675208
3 TP53 NM_000546.5(TP53):c.833C>A (p.Pro278His) SNV Likely pathogenic 376646 rs876659802 17:7577105-7577105 17:7673787-7673787
4 TP53 NM_000546.6(TP53):c.845G>C (p.Arg282Pro) SNV Likely pathogenic 376659 rs730882008 17:7577093-7577093 17:7673775-7673775
5 TP53 NM_000546.5(TP53):c.731G>T (p.Gly244Val) SNV Likely pathogenic 376601 rs985033810 17:7577550-7577550 17:7674232-7674232
6 TP53 NM_000546.5(TP53):c.823T>C (p.Cys275Arg) SNV Likely pathogenic 376584 rs1057519983 17:7577115-7577115 17:7673797-7673797
7 TP53 NM_001276697.2(TP53):c.-75T>C SNV Likely pathogenic 376560 rs1057519975 17:7578527-7578527 17:7675209-7675209
8 IDH1 NM_001282386.1(IDH1):c.394C>T (p.Arg132Cys) SNV Likely pathogenic 375891 rs121913499 2:209113113-209113113 2:208248389-208248389
9 TP53 NM_000546.5(TP53):c.763A>T (p.Ile255Phe) SNV Likely pathogenic 376621 rs1057519995 17:7577518-7577518 17:7674200-7674200
10 TP53 NM_000546.6(TP53):c.583A>T SNV Likely pathogenic 376617 rs942158624 17:7578266-7578266 17:7674948-7674948
11 TP53 NM_000546.5(TP53):c.818G>T (p.Arg273Leu) SNV Likely pathogenic 376655 rs28934576 17:7577120-7577120 17:7673802-7673802
12 TP53 NM_000546.5(TP53):c.584T>C (p.Ile195Thr) SNV Likely pathogenic 216077 rs760043106 17:7578265-7578265 17:7674947-7674947
13 PIK3CA NM_006218.4(PIK3CA):c.3128T>C (p.Met1043Thr) SNV Likely pathogenic 376486 rs1057519937 3:178952073-178952073 3:179234285-179234285
14 TP53 NM_000546.5(TP53):c.526T>C (p.Cys176Arg) SNV Likely pathogenic 376573 rs967461896 17:7578404-7578404 17:7675086-7675086
15 TP53 NM_001276697.2(TP53):c.-57T>C SNV Likely pathogenic 376565 rs1057519978 17:7578509-7578509 17:7675191-7675191
16 TP53 NM_000546.5(TP53):c.844C>G (p.Arg282Gly) SNV Likely pathogenic 140821 rs28934574 17:7577094-7577094 17:7673776-7673776
17 TP53 NM_000546.5(TP53):c.646G>T (p.Val216Leu) SNV Likely pathogenic 376670 rs730882025 17:7578203-7578203 17:7674885-7674885
18 TP53 NM_000546.5(TP53):c.818G>C (p.Arg273Pro) SNV Likely pathogenic 231060 rs28934576 17:7577120-7577120 17:7673802-7673802
19 TP53 NM_000546.5(TP53):c.707A>G (p.Tyr236Cys) SNV Likely pathogenic 376693 rs730882026 17:7577574-7577574 17:7674256-7674256
20 TP53 NM_000546.5(TP53):c.730G>C (p.Gly244Arg) SNV Likely pathogenic 376602 rs1057519989 17:7577551-7577551 17:7674233-7674233
21 TP53 NM_000546.6(TP53):c.722C>G (p.Ser241Cys) SNV Likely pathogenic 177791 rs28934573 17:7577559-7577559 17:7674241-7674241
22 TP53 NM_000546.5(TP53):c.403T>A (p.Cys135Ser) SNV Likely pathogenic 376562 rs1057519975 17:7578527-7578527 17:7675209-7675209
23 TP53 NM_000546.5(TP53):c.832C>G (p.Pro278Ala) SNV Likely pathogenic 376645 rs17849781 17:7577106-7577106 17:7673788-7673788
24 TP53 NM_000546.5(TP53):c.518T>C (p.Val173Ala) SNV Likely pathogenic 376017 rs1057519747 17:7578412-7578412 17:7675094-7675094
25 TP53 NM_000546.5(TP53):c.374C>T (p.Thr125Met) SNV Likely pathogenic 183748 rs786201057 17:7579313-7579313 17:7675995-7675995
26 TP53 NM_000546.5(TP53):c.585C>G (p.Ile195Met) SNV Likely pathogenic 376620 rs1057519994 17:7578264-7578264 17:7674946-7674946
27 ALK NM_004304.5(ALK):c.3383G>C (p.Gly1128Ala) SNV Likely pathogenic 18084 rs113994088 2:29445450-29445450 2:29222584-29222584
28 TP53 NM_000546.5(TP53):c.734G>C (p.Gly245Ala) SNV Likely pathogenic 265357 rs121912656 17:7577547-7577547 17:7674229-7674229
29 TP53 NM_000546.5(TP53):c.638G>T (p.Arg213Leu) SNV Likely pathogenic 376650 rs587778720 17:7578211-7578211 17:7674893-7674893
30 TP53 NM_000546.5(TP53):c.613T>C (p.Tyr205His) SNV Likely pathogenic 376685 rs1057520008 17:7578236-7578236 17:7674918-7674918
31 TP53 NM_000546.5(TP53):c.857A>C (p.Glu286Ala) SNV Likely pathogenic 376593 rs1057519985 17:7577081-7577081 17:7673763-7673763
32 TP53 NM_001276697.2(TP53):c.-57T>A SNV Likely pathogenic 376567 rs1057519978 17:7578509-7578509 17:7675191-7675191
33 TP53 NM_000546.5(TP53):c.833C>T (p.Pro278Leu) SNV Likely pathogenic 232497 rs876659802 17:7577105-7577105 17:7673787-7673787
34 TP53 NM_000546.5(TP53):c.743G>T (p.Arg248Leu) SNV Likely pathogenic 230253 rs11540652 17:7577538-7577538 17:7674220-7674220
35 PIK3R1 NM_181523.3(PIK3R1):c.1126G>C (p.Gly376Arg) SNV Likely pathogenic 376065 rs1057519757 5:67589138-67589138 5:68293310-68293310
36 ALK NM_004304.5(ALK):c.3575G>C (p.Arg1192Pro) SNV Likely pathogenic 18085 rs113994089 2:29443642-29443642 2:29220776-29220776
37 TP53 NM_000546.5(TP53):c.824G>A (p.Cys275Tyr) SNV Likely pathogenic 215997 rs863224451 17:7577114-7577114 17:7673796-7673796
38 TP53 NM_000546.5(TP53):c.721T>G (p.Ser241Ala) SNV Likely pathogenic 376665 rs1057520002 17:7577560-7577560 17:7674242-7674242
39 EGFR NM_005228.5(EGFR):c.1793G>C (p.Gly598Ala) SNV Likely pathogenic 376399 rs139236063 7:55233043-55233043 7:55165350-55165350
40 IDH2 NM_001289910.1(IDH2):c.358A>G (p.Arg120Gly) SNV Likely pathogenic 376439 rs1057519906 15:90631839-90631839 15:90088607-90088607
41 TP53 NM_000546.5(TP53):c.824G>T (p.Cys275Phe) SNV Likely pathogenic 376582 rs863224451 17:7577114-7577114 17:7673796-7673796
42 EGFR NM_005228.5(EGFR):c.866C>T (p.Ala289Val) SNV Likely pathogenic 376209 rs149840192 7:55221822-55221822 7:55154129-55154129
43 IDH1 NM_001282386.1(IDH1):c.394C>G (p.Arg132Gly) SNV Likely pathogenic 375892 rs121913499 2:209113113-209113113 2:208248389-208248389
44 TP53 NM_000546.5(TP53):c.646G>A (p.Val216Met) SNV Likely pathogenic 182965 rs730882025 17:7578203-7578203 17:7674885-7674885
45 TP53 NM_000546.5(TP53):c.821T>A (p.Val274Asp) SNV Likely pathogenic 376675 rs1057520006 17:7577117-7577117 17:7673799-7673799
46 TP53 NM_000546.5(TP53):c.797G>T (p.Gly266Val) SNV Likely pathogenic 233303 rs193920774 17:7577141-7577141 17:7673823-7673823
47 TP53 NM_000546.5(TP53):c.613T>A (p.Tyr205Asn) SNV Likely pathogenic 376684 rs1057520008 17:7578236-7578236 17:7674918-7674918
48 IDH2 NM_001289910.1(IDH2):c.358A>T (p.Arg120Trp) SNV Likely pathogenic 376438 rs1057519906 15:90631839-90631839 15:90088607-90088607
49 TP53 NM_000546.5(TP53):c.638G>C (p.Arg213Pro) SNV Likely pathogenic 231214 rs587778720 17:7578211-7578211 17:7674893-7674893
50 TP53 NM_000546.5(TP53):c.721T>C (p.Ser241Pro) SNV Likely pathogenic 376664 rs1057520002 17:7577560-7577560 17:7674242-7674242

Copy number variations for Brain Cancer from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 112045 17 37800000 41900000 Gain Brain cancer
2 179187 8 123863081 124055936 Deletion RAF1 Brain cancer
3 205638 6 130400000 131300000 Deletion Brain cancer
4 233881 8 128747764 129113498 Amplification MYC Brain cancer
5 234173 8 131500000 139900000 Amplification KHDRBS3 Brain cancer
6 254105 9 51800000 140273252 Deletion Brain cancer

Expression for Brain Cancer

Search GEO for disease gene expression data for Brain Cancer.

Pathways for Brain Cancer

Pathways related to Brain Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 131)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.92 TP53 PTEN PIK3R1 NRAS H3-3A EPHB2
2
Show member pathways
13.65 PIK3R1 NRAS H3-3A EPHB2 EGFR CTNNB1
3
Show member pathways
13.62 TP53 PTPN11 PIK3R1 PIK3CA NRAS H3-3A
4
Show member pathways
13.59 PTPN11 PIK3R1 PIK3CA NRAS H3-3A EPHB2
5
Show member pathways
13.45 TP53 PTPN11 PIK3R1 PIK3CA NRAS EGFR
6
Show member pathways
13.38 PIK3R1 NRAS EPHB2 EGFR CTNNB1 BRAF
7
Show member pathways
13.21 TP53 PTPN11 PTEN PIK3R1 PIK3CA EGFR
8
Show member pathways
13.18 TP53 PTEN PIK3R1 PIK3CA NRAS EGFR
9
Show member pathways
13.17 TP53 PTEN PIK3R1 NRAS EGFR BRAF
10
Show member pathways
13.16 TP53 PIK3R1 PIK3CA NRAS EGFR CTNNB1
11
Show member pathways
13.08 TP53 PTEN PIK3R1 PIK3CA NRAS EGFR
12
Show member pathways
13.05 TP53 PIK3R1 PIK3CA NRAS EGFR CTNNB1
13
Show member pathways
13 PTPN11 PTEN PIK3R1 PIK3CA NRAS EGFR
14
Show member pathways
12.99 PTEN PIK3R1 PIK3CA NRAS EGFR CTNNB1
15
Show member pathways
12.97 PTEN PIK3R1 PIK3CA NRAS EGFR BRAF
16
Show member pathways
12.94 PIK3R1 PIK3CA NRAS EGFR BRAF
17
Show member pathways
12.87 PTPN11 PTEN PIK3R1 PIK3CA BRAF
18
Show member pathways
12.82 PTPN11 PIK3R1 PIK3CA NRAS EGFR CTNNB1
19
Show member pathways
12.81 TP53 PTPN11 PTEN PIK3R1 PIK3CA NRAS
20
Show member pathways
12.77 TP53 PIK3R1 NRAS EGFR BRAF
21
Show member pathways
12.76 TP53 PTEN PIK3R1 PIK3CA NRAS EGFR
22 12.75 PIK3R1 PIK3CA NRAS EGFR BRAF
23
Show member pathways
12.74 PIK3R1 PIK3CA NRAS EGFR CTNNB1
24
Show member pathways
12.72 TP53 PTPN11 PTEN PIK3R1 PIK3CA NRAS
25
Show member pathways
12.7 PTPN11 PTEN PIK3R1 PIK3CA NRAS
26
Show member pathways
12.69 PTPN11 PIK3R1 PIK3CA NRAS BRAF
27
Show member pathways
12.69 PTPN11 PTEN PIK3R1 PIK3CA NRAS EGFR
28
Show member pathways
12.69 TP53 PTPN11 PTEN PIK3R1 PIK3CA NRAS
29
Show member pathways
12.68 TP53 PTPN11 PIK3R1 PIK3CA NRAS EGFR
30
Show member pathways
12.64 TP53 PTEN PIK3R1 PIK3CA NRAS EGFR
31 12.64 TP53 PTEN PIK3R1 PIK3CA NRAS EGFR
32
Show member pathways
12.62 PTPN11 PIK3R1 PIK3CA NRAS BRAF
33
Show member pathways